SL Science Holding Limited closed at $1.22 on Nov 3, down 3.94%, 41.1% below its highest close since Sep 11. Volume of 7.4K shares was 0.17× its 20-day average (below normal).
Split-adjusted performance: -23.3% over one month.
Short interest was 36.6K shares at the Oct 15 settlement, down 28.9% from the prior report (0.0% of float, 1.0 days to cover).
No recent articles focused on SL Science Holding Limited.
Quick answers
What does SL Science Holding Limited do?
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products.
What is SLBT's market cap?
$684.13M, based on the Nov 3 close of $1.22.
How much of SLBT is sold short?
36.6K shares, 0.0% of float, as of Oct 15, 2026.
About SL Science Holding Limited
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
